Interleukin-1 Revisited Further Insights Into its Role in Atherosclerosis and as a Potential Therapeutic Target for Treatment

被引:2
|
作者
Ray, Kausik K. [1 ]
机构
[1] St Georges Univ London, Cardiovasc Sci Res Ctr, London SW17 ORE, England
关键词
atherosclerosis; interleukin; lipoprotein(a); oxidation; oxidized phospholipids; LOW-DENSITY LIPOPROTEINS; CORONARY-ARTERY-DISEASE; OXIDIZED PHOSPHOLIPIDS; MESSENGER-RNA; EXPRESSION; RISK; OUTCOMES; STROKE;
D O I
10.1016/j.jacc.2014.01.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Stable obstructive coronary artery disease (CAD) and acute coronary syndromes (ACS) result from the complex interplay between genetic factors and environmental exposures over time. However, few studies have provided clarity around the interactions between different genes and environmental exposures and the resultant effects on cardiovascular (CV) phenotype. Even the model of gene-environment interaction is likely oversimplistic as there are likely to be multiple genes involved in: 1) the initiation of atherosclerosis; and 2) modification of the subclinical course, inter-playing with different environmental factors to influence the timing and the type of clinical presentation (Fig. 1). In this issue of the Journal, Tsimikas et al. (1) link for the first time the potential interactions between genetic factors influencing inflammation and exposure to modified lipids, and how this may influence the development of CAD and CV events.
引用
收藏
页码:1735 / 1738
页数:4
相关论文
共 50 条
  • [21] Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment
    Lewis, Anne M.
    Varghese, Sheelu
    Xu, Hui
    Alexander, H. Richard
    JOURNAL OF TRANSLATIONAL MEDICINE, 2006, 4 (1)
  • [22] MECHANISTIC INSIGHTS TO THE DIFFERENTIAL EFFECTS OF INTERLEUKIN-1 ISOFORMS ON EXPERIMENTAL ATHEROSCLEROSIS
    Vromman, Amelie
    Ruvkun, Victoria
    Shvartz, Eugenia
    Wojtkiewicz, Gregory
    Masson, Gustavo Santos
    Tesmenitsky, Yevgenia
    Gram, Hermann
    Folco, Eduardo
    Swirski, Filip
    Nahrendorf, Matthias
    Sukhova, Galina
    Libby, Peter
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 105 - 105
  • [23] Interleukin-1 and Stroke: Biomarker, Harbinger of Damage, and Therapeutic Target
    Denes, Adam
    Pinteaux, Emmanuel
    Rothwell, Nancy J.
    Allan, Stuart M.
    CEREBROVASCULAR DISEASES, 2011, 32 (06) : 517 - 527
  • [24] Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis
    Goncalves, Nadia Pereira
    Vieira, Paulo
    Saraiva, Maria Joao
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2014, 21 (03): : 175 - 184
  • [25] INHIBITION BY PROBUCOL OF INTERLEUKIN-1 SECRETION AND ITS IMPLICATION IN ATHEROSCLEROSIS
    KU, G
    DOHERTY, NS
    WOLOS, JA
    JACKSON, RL
    SCHMIDT, LF
    HENDRICKS, D
    AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (03): : B77 - B81
  • [26] INTERLEUKIN-1 AND ITS ROLE IN HUMAN PATHOLOGY
    NASONOV, EL
    TERAPEVTICHESKII ARKHIV, 1987, 59 (12) : 112 - 117
  • [27] ABCG1 - A potential therapeutic target for atherosclerosis
    Ni, Zhan-ling
    Zhao, Shui-ping
    Wu, Zhihong
    MEDICAL HYPOTHESES, 2007, 69 (01) : 214 - 217
  • [29] Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target
    Macphee, CH
    Nelson, J
    Zalewski, A
    CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (02) : 154 - 161
  • [30] The interleukin-1 receptor signaling complex as a potential therapeutic target for the transition from cardiac hypertrophy to failure
    Long, CS
    JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 69A - 69A